p53 mutations in ovarian cancer: a late event?
- PMID: 1923532
p53 mutations in ovarian cancer: a late event?
Abstract
Using a combination of polymerase chain reaction and single-strand conformation polymorphism techniques we analyzed 34 ovarian cancer samples (30 primary tumors and four matched metastases) for the presence of mutations in exons 5, 6, 7, 8 and 9 of the p53 gene. Mutations in this portion of the gene are known to lead to the loss of the oncosuppressive potential of p53. Thirty-six percent (11/30) of the ovarian carcinomas tested presented a mutated p53 allele. Mutations were clustered in exons 5 and 7 to the exclusion of the other exons screened. Most mutations (10/11) were point mutations, but no preferential pattern of nucleotide substitution could be observed. In three tumors the mutation of one allele was concomitant with the loss of the wild-type counterpart. Another sample presented both alleles independently mutated. These observations are in agreement with the recessive nature of the p53 mutation. However, analysis of tissue sections from two tumors showed that the portion composed of 100% cancer cells could hold both the mutated and the wild-type form. Moreover analysis of serial sections gave evidence of a heterogeneous cellular content in one of these tumors, suggesting that p53 mutations may, in some cases, occur late during ovarian cancer evolution. It is, moreover, noticeable that, in matched sets of primary tumors and metastases, the same mutation was observed in both tumor samples. Therefore, even as a late event, p53 mutation occurs before metastatic spread.
Similar articles
-
p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases.Cancer Res. 1991 Nov 1;51(21):5800-5. Cancer Res. 1991. PMID: 1933850
-
p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.Cancer Res. 1993 Jul 1;53(13):3103-8. Cancer Res. 1993. PMID: 8319218
-
[Mutations of p53 gene exons 5 to 8 in human ovarian cancer and its clinical significance].Zhonghua Fu Chan Ke Za Zhi. 1996 Nov;31(11):660-3. Zhonghua Fu Chan Ke Za Zhi. 1996. PMID: 9387525 Chinese.
-
[Genetic abnormalities in ovarian tumors].Nihon Rinsho. 2004 Oct;62 Suppl 10:449-53. Nihon Rinsho. 2004. PMID: 15535285 Review. Japanese. No abstract available.
-
Molecular approaches to diagnosis and management of ovarian cancer.Cancer Metastasis Rev. 1997 Jun;16(1-2):81-107. doi: 10.1023/a:1005796307286. Cancer Metastasis Rev. 1997. PMID: 9156281 Review.
Cited by
-
Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas.Virchows Arch A Pathol Anat Histopathol. 1992;421(3):223-8. doi: 10.1007/BF01611179. Virchows Arch A Pathol Anat Histopathol. 1992. PMID: 1413488
-
Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas.Am J Pathol. 1993 Mar;142(3):725-32. Am J Pathol. 1993. PMID: 8456936 Free PMC article.
-
Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status.Virchows Arch. 1995;425(6):603-9. doi: 10.1007/BF00199350. Virchows Arch. 1995. PMID: 7697217
-
Heterogeneity of p53 mutational status in esophageal squamous cell carcinoma.Jpn J Cancer Res. 1998 Apr;89(4):405-10. doi: 10.1111/j.1349-7006.1998.tb00578.x. Jpn J Cancer Res. 1998. PMID: 9617346 Free PMC article.
-
Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.BMC Med Genet. 2019 Sep 2;20(1):150. doi: 10.1186/s12881-019-0881-0. BMC Med Genet. 2019. PMID: 31477031 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous